AI assistant
AMGEN INC — Director's Dealing 2024
Feb 13, 2024
29819_dirs_2024-02-12_ffd22736-fa4f-41d2-8375-12da279a450b.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: AMGEN INC (AMGN)
CIK: 0000318154
Period of Report: 2024-02-09
Reporting Person: Bradner James E. (EVP, R&D, & Chief Sci. Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2024-02-09 | Common Stock | A | 8587 | — | Acquired | 8587 | Direct |
| 2024-02-09 | Common Stock | A | 13806 | — | Acquired | 22393 | Direct |
Footnotes
F1: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and vest in three annual installments of 33%, 33% and 34% on 2/9/2026, 2/9/2027 and 2/9/2028,
respectively.
F2: These shares include the following RSUs granted under the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan: 8,587 RSUs which will vest in installments of 2,833 on 2/9/2026, 2,834 on 2/9/2027, and 2,920 on 2/9/2028; and 13,806 RSUs which will vest in installments of 4,555 on 2/9/2026, 4,556 on 2/9/2027, and 4,695 on 2/9/2028. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.